Ventyx biosciences reports clinical data for its nlrp3 inhibitor portfolio and provides pipeline updates at virtual investor event

Vtx3232 was well-tolerated in the phase 1 trial with robust target coverage achieved in both plasma and csf; ventyx is planning to initiate phase 2a trials in parkinson's disease and obesity in h2 2024
VTYX Ratings Summary
VTYX Quant Ranking